The Middle East and Africa (MEA) flu diagnostic and treatment market is expected to surge at a CAGR of 10.89% throughout the forecast period. The market is projected to reach a value of US$7,045.595 million by 2027, from US$3,416.657 million in 2020.
The growing investments in the healthcare sector are one of the prime drivers for the Middle East and Africa (MEA) flu diagnostics and treatment market growth. Furthermore, increasing government support to boost the healthcare sector and improve the quality of healthcare across the numerous countries in the region is also contributing to the market growth for flu diagnostic and treatment in the Middle East and Africa (MEA) region. For instance, the government of Saudi Arabia is taking numerous initiatives to boost the private healthcare sector of the country as their inclination towards economic diversification and also to reduce the dependence on the public sector is also one of the key factors which is anticipated to propel the growth opportunities for the market to surge in the Middle East and Africa region throughout the forecast period and beyond. Furthermore, in many countries, the unavailability of well-established public healthcare is leading to the rising adoption of private healthcare services, such as in South Africa and Iran, among others. The growth in private health spending in numerous countries is also projected to show propelling growth opportunities during the coming years. For instance, in Israel, the proportion of private spending reached around 40% (Source: Israel Central Bureau of Statistics). This, in turn, is projected to augment the demand for advanced healthcare services, thereby positively impacting the market growth in the Middle East and Africa region.
Rising healthcare expenditure is expected to drive the market growth
Healthcare expenditure plays an important role in driving the flu diagnostic and treatment market in the region. The rising healthcare expenditure in various countries in the region further shows the potential for the market to grow as the rising healthcare expenditure indicates an increase in the demand for costly medical services and treatments, which is positively impacting the market growth for the coming years. For instance, according to the World Bank Group, the current healthcare expenditure per capita (current US$) in Israel reached US$2,387.14 in 2016 from 1,580.635 in 2006. Similarly, in Saudi Arabia, it increased from US$554.256 in 2006 to US$1,147.333 by 2016. In addition, the country also allocated around US$39.2 million in 2018, especially for the Healthcare and Social Development Sector, an increase of 10% from the previous year, which is also amplifying the market growth in the region throughout the forecast period.
Type A flu holds a notable share in the market
On the basis of the type of flu, the Middle East and African flu diagnostic and treatment markets have been classified into Type A and Type B. The Type A segment is anticipated to hold a noteworthy market share due to the fact that this is the most common type of influenza virus diagnosed throughout the various countries of the Middle East and Africa region. In addition, the number of diagnosed cases with type the flu is also higher in comparison with the number of type B flu in the region which is one of the key factors supporting the growth of the type A segment.
Qatar is anticipated to show noteworthy growth over the forecast period
On the basis of the country, the Middle East and Africa flu diagnostic and treatment market has been segmented on the basis of Saudi Arabia, Israel, UAE, Qatar, Iran, and South Africa, among others. Qatar is projected to show noteworthy growth in the market throughout the next five years due to the well-established healthcare sector and highly advanced healthcare infrastructure of the country. Israel is also projected to show decent growth during the forecast period as the country’s focus on providing quality healthcare to everyone supports the flu diagnostic and treatment market growth in Israel.
Key Developments in the Market
COVID-19 had a positive impact on the Middle East and Africa Flu Diagnostics and Treatment market. The swift taken by the respective local government to have the population receive flu vaccines in order to prevent the seasonal flu from spreading amid the prevailing pandemic added impetus to the market growth. The initiatives taken MoHAP, as mentioned above, is the best example of this. Additionally, because COVID and influenza share many of the same symptoms, there was an upsurge in the need for SARS-CoV-2 and influenza diagnostic kits. Such elements had a favourable impact on the market.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2020 | US$3,416.657 million |
| Market Size Value in 2027 | US$7,045.595 million |
| Growth Rate | CAGR of 10.89% from 2020 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type of Flu, Offering, Age Group, End-User, And Country |
| Regions Covered | Saudi Arabia, Israel, UAE, Qatar, Iran, South Africa, Others |
| Companies Covered | F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, 3M[1], SA Scientific, Meridian Bioscience |
| Customization Scope | Free report customization with purchase |
Key Market Segmentation